Stocks
Deciphera Pharmaceuticals Financial Statements (DCPH) |
||||||||||
| Deciphera Pharmaceuticalssmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 09.03.2020 | 09.02.2021 | 08.02.2022 | 07.02.2023 | 07.02.2024 | 10.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 25.0 | 42.1 | 96.1 | 134.0 | 163.4 | 174.9 | |||
| Operating Income, bln rub | -200.7 | -271.2 | -300.1 | -182.7 | -211.0 | -206.5 | ||||
| EBITDA, bln rub | ? | -192.2 | -264.2 | -300.1 | -182.7 | -208.9 | -203.9 | |||
| Net profit, bln rub | ? | -191.5 | -266.5 | -296.8 | -178.9 | -194.9 | -190.4 | |||
| OCF, bln rub | ? | -149.3 | -239.7 | -240.8 | -152.9 | -146.7 | -151.8 | |||
| CAPEX, bln rub | ? | 4.94 | 5.32 | 5.97 | 0.841 | 0.778 | 0.564 | |||
| FCF, bln rub | ? | -154.2 | -245.0 | -246.8 | -153.7 | -147.5 | -152.4 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 225.7 | 313.1 | 393.3 | 308.0 | 370.6 | 374.5 | ||||
| Cost of production, bln rub | 0.830 | 0.225 | 2.93 | 8.77 | 3.73 | 6.93 | ||||
| R&D, bln rub | 157.6 | 199.0 | 257.0 | 187.8 | 234.1 | 236.7 | ||||
| Interest expenses, bln rub | 0.067 | 0.000 | 0.000 | 4.51 | 0.000 | 3.65 | ||||
| Assets, bln rub | 622.4 | 642.4 | 429.5 | 454.0 | 473.6 | 420.9 | ||||
| Net Assets, bln rub | ? | 546.5 | 543.7 | 304.7 | 341.7 | 350.9 | 316.1 | |||
| Debt, bln rub | 17.7 | 31.2 | 30.9 | 29.1 | 25.9 | 25.0 | ||||
| Cash, bln rub | 579.6 | 551.9 | 285.6 | 324.5 | 306.2 | 272.5 | ||||
| Net debt, bln rub | -561.9 | -520.7 | -254.8 | -295.4 | -280.3 | -247.5 | ||||
| Ordinary share price, rub | 62.2 | 57.1 | 9.77 | 16.4 | 16.1 | 11.8 | ||||
| Number of ordinary shares, mln | 42.9 | 55.8 | 58.1 | 75.5 | 85.1 | 87.4 | ||||
| Market cap, bln rub | 2 668 | 3 183 | 567 | 1 237 | 1 372 | 1 027 | ||||
| EV, bln rub | ? | 2 106 | 2 663 | 313 | 942 | 1 092 | 779 | |||
| Book value, bln rub | 546 | 544 | 305 | 342 | 351 | 316 | ||||
| EPS, rub | ? | -4.47 | -4.78 | -5.11 | -2.37 | -2.29 | -2.18 | |||
| FCF/share, rub | -3.60 | -4.39 | -4.25 | -2.04 | -1.73 | -1.74 | ||||
| BV/share, rub | 12.7 | 9.75 | 5.25 | 4.53 | 4.13 | 3.62 | ||||
| EBITDA margin, % | ? | -768.8% | -627.7% | -312.1% | -136.3% | -127.9% | -116.6% | |||
| Net margin, % | ? | -766.0% | -633.2% | -308.7% | -133.5% | -119.3% | -108.9% | |||
| FCF yield, % | ? | -5.78% | -7.70% | -43.5% | -12.4% | -10.7% | -14.8% | |||
| ROE, % | ? | -35.0% | -49.0% | -97.4% | -52.4% | -55.6% | -60.2% | |||
| ROA, % | ? | -30.8% | -41.5% | -69.1% | -39.4% | -41.2% | -45.2% | |||
| P/E | ? | -13.9 | -11.9 | -1.91 | -6.92 | -7.04 | -5.39 | |||
| P/FCF | -17.3 | -13.0 | -2.30 | -8.05 | -9.30 | -6.74 | ||||
| P/S | ? | 106.7 | 75.6 | 5.90 | 9.23 | 8.40 | 5.87 | |||
| P/BV | ? | 4.88 | 5.86 | 1.86 | 3.62 | 3.91 | 3.25 | |||
| EV/EBITDA | ? | -11.0 | -10.1 | -1.04 | -5.16 | -5.23 | -3.82 | |||
| Debt/EBITDA | 2.92 | 1.97 | 0.85 | 1.62 | 1.34 | 1.21 | ||||
| R&D/CAPEX, % | 3 194% | 3 743% | 4 306% | 22 333% | 30 093% | 41 976% | ||||
| CAPEX/Revenue, % | 19.7% | 12.6% | 6.21% | 0.63% | 0.48% | 0.32% | ||||
| Deciphera Pharmaceuticals shareholders | ||||||||||
